Disc Medicine will pursue traditional U.S. approval for bitopertin after the FDA declined to approve the rare disease drug under an accelerated review pathway, with a potential decision expected around mid-2027.
The FDA declined to approve Disc Medicine's bitopertin for erythropoietic protoporphyria on February 13, 2026, citing insufficient evidence linking biomarker reductions to clinical benefit. The company will pursue traditional approval using Phase 3 APOLLO trial data expected in Q4 2026.
The FDA rejected Disc Medicine's bitopertin for erythropoietic protoporphyria, citing uncertainties about clinical benefit despite the drug receiving a priority review voucher. The company will pursue traditional approval with Phase 3 data expected in late 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07099196 |
Impact of Virtual Reality on Pain and Anxiety During Intravenous Cannulation Procedures Among Thalassemia Patients in UAE. |
COMPLETED | NA |
| NCT06820515 |
ATHNdataset Registry |
RECRUITING | |
| NCT03520712 |
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 |
TERMINATED | PHASE1/PHASE2 |
| NCT03518294 |
NASH Fitness Intervention in Thrombosis Trial (NASHFit) |
COMPLETED | NA |
| NCT03176849 |
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT |
COMPLETED | PHASE4 |
